×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AnHeart and Nippon Kayaku enter taletrectinib licence deal
Pharmaceutical Technology
AnHeart Therapeutics and Nippon Kayaku have signed an exclusive agreement for the former's investigational therapy, taletrectinib.
6 months ago
AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
Business Wire
AnHeart will be responsible for the clinical development of taletrectinib for ROS1-positive NSCLC and for supplying taletrectinib to Nippon...
6 months ago
BioCheetah and Nippon Kayaku to develop new bladder cancer test
Medical Device Network
Named VECanDx ELISA, the non-invasive urine test is developed by BioCheetah for adults experiencing haematuria or with a previous history of...
4 months ago
Henkel Sells Semiconductor Cleaning to Nippon Kayaku
CHEManager
05.02.2020 -. Henkel Adhesives Technologies has officially opened a new ... Germany's Henkel has signed a deal to sell its LCD and semiconductor cleaning...
51 months ago
Eiger BioPharmaceuticals Announces License Agreement with Nippon Kayaku to Develop Bestatin™ (ubenimex) for ...
PR Newswire
Share this article. Share toX. Share this article. Share toX ... PALO ALTO, Calif., Nov. 9, 2015 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. today...
102 months ago
Nippon Kayaku PhII breast cancer candidate misses endpoint
Fierce Pharma
Tokyo-based Nippon Kayaku said a Phase III study of in-licensed breast cancer candidate NK105 missed its primary endpoint--with the...
94 months ago
Celltrion, Nippon Kayaku to sell Rituxan biosimilar in Japan
The Korea Herald
South Korea's Celltrion said Thursday it has selected Japanese drugmaker Nippon Kayaku to handle the sales of its Truxima, a biosimilar copy...
84 months ago
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
Business Wire
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02) ... TOKYO--(BUSINESS WIRE)--Solasia...
30 months ago
Biosimilar Trastuzumab CT-P6 Launches in Japan, But Not For Breast Cancer
Center for Biosimilars®
Nippon Kayaku, a Japanese-based drug developer, announced yesterday that it has launched Celltrion's biosimilar trastuzumab (Herceptin)...
68 months ago
Research Report on Automotive SRS Airbag Inflator Market Size 2024-2030: Supply-Demand Trends, Regional ...
SOUTHEAST - NEWS CHANNEL NEBRASKA
Automotive SRS Airbag Inflator Market Survey Report segmented by Types, Applications, and Manufactures (Autoliv, Daicel Corporation, ZF TRW, Nippon Kayaku,...
1 week ago